Results 91 to 100 of about 108,257 (197)
Capacity scaling law by multiuser diversity in cognitive radio systems [PDF]
arXiv, 2010 This paper analyzes the multiuser diversity gain in a cognitive radio (CR) system where secondary transmitters opportunistically utilize the spectrum licensed to primary users only when it is not occupied by the primary users. To protect the primary users from the interference caused by the missed detection of primary transmissions in the secondary ...
arxiv
Transplant Infectious Disease, EarlyView.Prophylactic oral vancomycin was associated with reduced Clostridium difficile infection in allogeneic stem cell transplant patients. No differences in hospital‐acquired infections, mortality, GVHD, or rehospitalization were observed. It is a low‐cost, effective preventative strategy, though further prospective studies are needed to confirm safety and ...
Brendon Fusco +8 more
wiley +1 more source
Does angiogenesis matter in primary myelofibrosis?
Revista Brasileira de Hematologia e Hemoterapia, 2014 Primary myelofibrosis(PMF)isaclonalhematopoieticdisordercharacterized by an initial prefibrotic proliferative phase thatover time progresses to bone marrow fibrosis, extramedullaryhematopoiesis, peripheral blood cytopenias and an increasedrisk of developing acute myeloid leukemia (AML).
openaire +5 more sources
TP53 ‐Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk‐Stratification, and Management
American Journal of Hematology, Volume 100, Issue S4, Page 88-115, June 2025.ABSTRACT Alterations in the tumor suppressor gene TP53 are common in human cancers and are associated with an aggressive nature. Approximately 8%–12% of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) harbor TP53 mutations (TP53 mut) and present immense challenges due to inherent chemoresistance and poor outcomes.
Mithun Vinod Shah +2 more
wiley +1 more source
Indian Journal of Medical and Paediatric Oncology, 2018 Primary myelofibrosis (PMF) is a clonal disorder of a multipotent hematopoietic progenitor cell that occurs predominantly in the elderly age group. We report here an 11-year-old girl who presented with headache, fever, and splenomegaly.
Athanasios Tragiannidis +3 more
doaj +1 more source
Megakaryocytes morphology in idiopathic (primary) myelofibrosis
Reports of Practical Oncology & Radiotherapy, 2004 SummaryBackgroundThe cause of idiopathic myelofibrosis (IM) originating from a haemopoietic stem cells with development of secondary marrow fibrosis is unknown. Increased production of platelet-derived growth factor by megakaryocytes causes amplified activity of fibroblasts.
Iryna N. Kabachenko +2 more
openaire +2 more sources
American Journal of Hematology, Volume 100, Issue S4, Page 5-15, June 2025.ABSTRACT With the recent publication of new classification systems of hematopoietic neoplasms, understanding how recognition of disease entities has occurred over time and the subsequent development of formal disease classifications is of importance. This review focuses on the early recognition of myeloid disorders, especially chronic myeloid disorders,
Daniel A. Arber, Attilio Orazi
wiley +1 more source
Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives
American Journal of Hematology, Volume 100, Issue S4, Page 30-50, June 2025.ABSTRACT Myelofibrosis (MF) is a myeloproliferative neoplasm that is accompanied by driver JAK2, CALR, or MPL mutations in more than 90% of cases, leading to constitutive activation of the JAK–STAT pathway. MF is a multifaceted disease characterized by trilineage myeloid proliferation with prominent megakaryocyte atypia and bone marrow fibrosis, as ...
Giuseppe G. Loscocco, Paola Guglielmelli
wiley +1 more source
American Journal of Hematology, Volume 100, Issue S4, Page 16-29, June 2025.ABSTRACT Allogeneic hematopoietic stem‐cell transplantation (HCT) remains the only potentially curative therapy for patients with myelodysplastic neoplasms (MDS) and myelofibrosis (MF) and is the standard care for eligible patients with higher‐risk disease. Despite significant advancements, both diseases pose unique challenges due to their clinical and
Nico Gagelmann, Nicolaus Kröger
wiley +1 more source
Topics of Interest in Women With Myeloproliferative Neoplasms
American Journal of Hematology, Volume 100, Issue S4, Page 74-87, June 2025.Women with MPN: life‐cycle phases, specific risks, and influencing factors. ABSTRACT Overview Sex and gender have emerged as central modifiers of disease biology, phenotype, and clinical outcomes in myeloproliferative neoplasms (MPNs). This review will uniquely highlight issues affecting women with MPN and articulate their relevant determinants ...
Natasha Szuber +2 more
wiley +1 more source